Replies to post #217544 on Biotech Values

[DewDiligence]

RVNC’s pro forma cash balance at 12/31/17=$289.3M. This figure consists of: $264.3M of net current assets on the 12/31/17 balance sheet (https://www.sec.gov/Archives/edgar/data/1479290/000147929018000038/rvnc1231201710k.htm#s4BDE5FBFF06F5892BCA0699CB0E34186 ); and $25M due from MYL pursuant to the companies’ Botox-biosimilar collaboration announced on 2/28/18 (#msg-138919580).

[DewDiligence]

RVNC 1Q18 results—cash=$269M:

http://investors.revance.com/releasedetail.cfm?ReleaseID=1066779

CC at 4:30pm ET.